The results showed that Patients in the program started on average at 1.7 days after symptom onset when assessed by NEWS over a 14-day treatment period.
The favipiravir treatment group improved by 79%, compared to 32.3% in the control group. The favipiravir group improved significantly faster. by half Patients who received favipiravir showed improvement from day 2 of treatment compared to 14 days in the control group.
The number of viral loads in patients treated with favipiravir was not significantly different from those in the control group. Until days 13 and 28 of treatment, it was found that the favipiravir group had lower viral loads.
SIDE EFFECTS A significant increase in uric acid levels was observed in patients treated with favipiravir compared to controls.